Coulter

Beckman Coulter Offers $4/High-throughput Antigen Test to Support U.S. Government Initiative to Expand COVID-19 Testing

Retrieved on: 
Thursday, March 18, 2021

Beckman Coulter announced in December that their $4 antigen test will be available to all customers and has a confirmed 93% positive predictive agreement (PPA) and 100% negative predictive agreement (NPA).

Key Points: 
  • Beckman Coulter announced in December that their $4 antigen test will be available to all customers and has a confirmed 93% positive predictive agreement (PPA) and 100% negative predictive agreement (NPA).
  • Only Beckman Coulter's $4 SARS-CoV-2 antigen test makes large-scale, serial testing programs feasible and affordable.
  • Beckman Coulter offers a unique combination of people, processes and solutions designed to elevate the performance of clinical laboratories and healthcare networks.
  • Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

Beckman Coulter Life Sciences launches next-generation CytoFLEX SRT Benchtop Cell Sorter

Retrieved on: 
Thursday, March 4, 2021

INDIANAPOLIS, March 4, 2021 /PRNewswire/ --Leading the way for more than 85 years, Beckman Coulter Life Sciences proudly announces the launch of its highly anticipated CytoFLEX SRT Benchtop Sorter-- the CytoFLEX that sorts, and features expanded laser and color options for use in labs of all sizes.

Key Points: 
  • INDIANAPOLIS, March 4, 2021 /PRNewswire/ --Leading the way for more than 85 years, Beckman Coulter Life Sciences proudly announces the launch of its highly anticipated CytoFLEX SRT Benchtop Sorter-- the CytoFLEX that sorts, and features expanded laser and color options for use in labs of all sizes.
  • A critical part of the development of the CytoFLEX SRT is the attention to design for reliability, according to Pavel Lorenzo, Senior Engineer in Service and Support for Beckman Coulter Life Sciences.
  • The CytoFLEX SRT joins the CytoFLEX, CytoFLEX S, and CytoFLEX LX benchtop Flow Cytometers by Beckman Coulter Life Sciences.
  • Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

Triton International Announces Retirement of David A. Coulter From Board of Directors

Retrieved on: 
Monday, March 1, 2021

March 1, 2021 Triton International Limited (NYSE:TRTN) today announced that David A. Coulter will retire from the Board of Directors at the expiration of his current term at the Companys annual general meeting on April 27, 2021.

Key Points: 
  • March 1, 2021 Triton International Limited (NYSE:TRTN) today announced that David A. Coulter will retire from the Board of Directors at the expiration of his current term at the Companys annual general meeting on April 27, 2021.
  • Mr. Coulter has been a director since 2015, having previously served as a director of Triton Container International Limited since 2011.
  • On behalf of the Board and management, I want to thank David for his combined 10 years of dedicated service to Triton.
  • We wish David and his family all the best following his retirement.

Beckman Coulter brings the productivity and efficiency benefits of large volume hematology analyzers to small- and medium-sized labs

Retrieved on: 
Monday, January 25, 2021

Compactly designed, the DxH 560 AL uses ~30% less counter space than other analyzers in its class.

Key Points: 
  • Compactly designed, the DxH 560 AL uses ~30% less counter space than other analyzers in its class.
  • Smaller labs can now reap the same efficiency and productivity benefits as larger labs without blowing the budget.
  • "The industry-leading functionality and auto-load capabilities of the DxH 560 AL enables smaller labs to reap the same efficiency and productivity benefits as their larger counterparts without blowing the budget."
  • Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

Pittcon 2021 Wallace H. Coulter Lecture

Retrieved on: 
Monday, January 18, 2021

PITTSBURGH, Jan. 18, 2021 /PRNewswire/ --Pittcon is honored to host Joseph B. Powell, Ph.D. as the 2021 Wallace H. Coulter Lecturer.

Key Points: 
  • PITTSBURGH, Jan. 18, 2021 /PRNewswire/ --Pittcon is honored to host Joseph B. Powell, Ph.D. as the 2021 Wallace H. Coulter Lecturer.
  • The 2021 Coulter Lecture is entitled The Industrial Laboratory for Energy and Chemicals: Past, Present, and Future.
  • The Wallace H. Coulter Lecture is a distinct feature of the annual Pittcon conference and exposition.
  • The 2021 Coulter Lecture is scheduled to begin at 5:00pm on March 8, 2021, taking place during Pittcon's annual conference and exposition, which is being presented virtually from March 812, 2021.

Beckman Coulter launches its semi-quantitative SARS-CoV-2 IgG II antibody test

Retrieved on: 
Monday, November 23, 2020

BREA, Calif., Nov.23, 2020 /PRNewswire/ --Beckman Coulter, a clinical diagnostics leader, today launched itsAccess SARS-CoV-2 IgG II assay that measures a patient's relative level of antibodies in response to a previous SARS-CoV-2 infection.

Key Points: 
  • BREA, Calif., Nov.23, 2020 /PRNewswire/ --Beckman Coulter, a clinical diagnostics leader, today launched itsAccess SARS-CoV-2 IgG II assay that measures a patient's relative level of antibodies in response to a previous SARS-CoV-2 infection.
  • The Access SARS-CoV-2 IgG II semi-quantitative assay is the latest addition to Beckman Coulter's full suite of testing solutions designed to provide valuable information to clinicians in their fight against COVID-19.
  • Results of the new Access SARS-CoV-2 IgG II test are delivered quickly on Beckman Coulter's award-winning immunoassay analyzers, including the DxI 800 high-throughput analyzer, which is capable of processing 200 samples per hour.
  • Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

DGAP-News: FIDURA Private Equity Funds: Successful sale of portfolio company m2p-labs GmbH to Beckman Coulter Life Sciences

Retrieved on: 
Friday, November 13, 2020

"Innovation defines our future," said Greg Milosevich, President, Beckman Coulter Life Sciences.

Key Points: 
  • "Innovation defines our future," said Greg Milosevich, President, Beckman Coulter Life Sciences.
  • We are pleased to have found in Beckman Coulter Life Sciences the ideal strategic partner to further realize the great potential of the m2p product portfolio.
  • Our buy-and-build strategy has thus been implemented extremely successfully, adds Klaus Ragotzky, Managing Director of lead investor FIDURA Private Equity Fonds.
  • Beckman Coulter Life Sciences develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing.

Beckman Coulter launches its SARS-CoV-2 IgM antibody test in countries accepting CE Mark and will begin shipping to diagnostics labs

Retrieved on: 
Tuesday, November 10, 2020

HIGH WYCOMBE, England, Nov. 10, 2020 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, today announced the launch of its Access SARS-CoV-2 Immunoglobulin M (IgM) assay in countries accepting the CE Mark.

Key Points: 
  • HIGH WYCOMBE, England, Nov. 10, 2020 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, today announced the launch of its Access SARS-CoV-2 Immunoglobulin M (IgM) assay in countries accepting the CE Mark.
  • The new IgM antibody test demonstrated 99.9% specificity with 1,400 negative samples and 98.3% sensitivity at 15-30 days post-symptom onset.
  • Beckman Coulter is also developing a SARS-CoV-2 antigen test and quantitative IgG assay.
  • Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

Beckman Coulter launches its SARS-CoV-2 IgM antibody test in countries accepting CE Mark and will begin shipping to diagnostics labs

Retrieved on: 
Tuesday, November 10, 2020

HIGH WYCOMBE, England, Nov. 10, 2020 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, today announced the launch of its Access SARS-CoV-2 Immunoglobulin M (IgM) assay in countries accepting the CE Mark.

Key Points: 
  • HIGH WYCOMBE, England, Nov. 10, 2020 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, today announced the launch of its Access SARS-CoV-2 Immunoglobulin M (IgM) assay in countries accepting the CE Mark.
  • The new IgM antibody test demonstrated 99.9% specificity with 1,400 negative samples and 98.3% sensitivity at 15-30 days post-symptom onset.
  • Beckman Coulter is also developing a SARS-CoV-2 antigen test and quantitative IgG assay.
  • Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

Dr. Amy Liao Receives the Wallace A. Coulter Award for Healthcare Innovation

Retrieved on: 
Friday, October 16, 2020

CHELMSFORD, Mass., Oct. 16, 2020 /PRNewswire/ --Brooks Automation, Inc. (Nasdaq: BRKS) announced today that Dr. Amy Liao, president of Brooks Life Science Services, has received the Biomedical Engineering Society's Wallace A. Coulter award for innovation in healthcare.

Key Points: 
  • CHELMSFORD, Mass., Oct. 16, 2020 /PRNewswire/ --Brooks Automation, Inc. (Nasdaq: BRKS) announced today that Dr. Amy Liao, president of Brooks Life Science Services, has received the Biomedical Engineering Society's Wallace A. Coulter award for innovation in healthcare.
  • The Coulter award recognizes an outstanding individual who has demonstrated a lifetime commitment to and made important contributions to patient healthcare.
  • "We are very proud to see Amy recognized by the Biomedical Engineering Society with this award," commented Steve Schwartz, CEO and president of Brooks Automation.
  • Dr. Amy Liao was appointed President of Brooks Life Sciences Services in April 2020.